TACR1 and prostate cancer: These results suggested that the elevation of NK1R was an adaptive response of prostate adenocarcinoma to antiandrogen therapies: during AR-targeted therapies, the loss of AR activity released the impediment and restored the expression of NK1R, then enhancing NK1R expression level in prostate cancer cells.